Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum

📈 Novo Nordisk shares have rallied approximately 27% since the author's previous coverage, significantly outperforming the broader market.

💊 Oral Wegovy captured roughly 89% of new U.S. prescriptions versus Eli Lilly's 11%, with weekly volumes of 153,050 compared to 19,550.

👥 More than 80% of oral Wegovy prescriptions came from new GLP-1 patients, expanding the total market instead of cannibalizing injectable products.

🌍 International approvals in the U.S., UAE, UK, and EU support a multi-market rollout expected to drive revenue growth into 2027.

⚠️ Consensus forecasts still predict Q2 revenue declining 8.9% and EPS falling 17.8% due to generic competition pressures on injectable sales.

📊 The article contrasts strong oral product momentum with near-term financial headwinds in the established injectable business.

Bullish Signals
  • Novo Nordisk shares have rallied approximately 27%, indicating strong market confidence and outperformance relative to the broader market.
  • Oral Wegovy has captured roughly 89% of new U.S. prescriptions, demonstrating dominant market share in this specific formulation segment.
  • Weekly prescription volumes for oral Wegovy reached 153,050, significantly higher than Eli Lilly's 19,550, highlighting superior commercial traction.
  • Over 80% of oral Wegovy prescriptions are from new GLP-1 patients, proving the product is successfully expanding the total addressable market rather than displacing existing revenue.
  • International regulatory approvals across the U.S., UAE, UK, and European Union enable a multi-market rollout that could sustain revenue growth into 2027.
Risk Factors
  • Consensus forecasts predict Q2 revenue will decline by 8.9%, reflecting near-term headwinds in the core injectable business.
  • EPS is expected to fall by 17.8% in Q2, driven by generic competition pressures impacting injectable sales volumes and pricing.
  • The projected financial declines suggest that current momentum in oral formulations has not yet fully offset losses in the established injectable portfolio for the upcoming quarter.
Full Analysis
Novo Nordisk shares have rallied approximately 27% since the author's last coverage, driven primarily by accelerating commercial momentum for its oral Wegovy formulation and expanding investor confidence. The article highlights that Novo Nordisk has captured roughly 89% of new U.S. prescriptions for oral Wegovy compared to Eli Lilly's 11%, with weekly prescription volumes of 153,050 versus 19,550 respectively. A key differentiator noted is that over 80% of oral Wegovy prescriptions are coming from patients who are new to GLP-1 therapy, indicating the product is expanding the overall market rather than cannibalizing existing injectable sales. This trend is supported by international regulatory approvals across the U.S., UAE, UK, and European Union, which facilitate a multi-market rollout expected to drive revenue growth into 2027. Despite this strong momentum in oral formulations, consensus financial forecasts still predict a decline in Q2 revenue of 8.9% and an earnings per share (EPS) drop of 17.8%. These projected declines are attributed to generic competition pressures affecting injectable sales, creating a mixed outlook where product innovation offsets but does not yet fully negate near-term headwinds in the core business.